France Has Not Invested Enough to Prepare for the Threat Posed by Alzheimer’s Disease

 The president of France Alzheimer, Joël Jaouen, and the director of the Global Coalition on Aging, Mike Hodin, warn in an op-ed for ‘Le Monde’ about the government’s disengagement in terms of financing disease prevention and access to care. This piece originally appeared in French.

 France, like almost every developed country in the world, is aging – a demographic fact that will lead to new public health challenges as significant as the COVID-19 pandemic. Today, more than 20% of the population is 65 years or older. By 2050, that number will rise to nearly 30%.

The aging of France all but guarantees a continuous rise in diseases that target the elderly. And perhaps the most devastating is Alzheimer’s – a disease that robs people of their memories, their independence, and their right to age with dignity. 

The big question is: Is France taking the actions needed to prepare for the looming Alzheimer’s pandemic? 

Unfortunately, the answer is a disappointing “no” – the current government is not investing adequately to prepare for the coming Alzheimer’s crisis. In fact, the country has taken several steps backward. And, in many ways, the crisis is already here. 

Today, more than 1.2 million people in France are living with Alzheimer’s and other dementias – a figure that will inevitably rise with the aging population. This devastating disease became the fourth leading cause of death in France in 2018, before the COVID-19 pandemic.

 To help stakeholders gauge France’s ability to meet this challenge, the Global Coalition on Aging and Alzheimer’s Disease International released the 2021 Alzheimer’s Innovation Readiness Index. The Index examines progress against several important measures of readiness, including a country’s policy and political commitment, early detection and diagnosis efforts, access to care and other factors. 

Overall, France currently ranks in the middle of the pack among European countries. Yet there are troubling signs that France risks falling behind. 

Most importantly, France’s political leaders have reneged on previous funding commitments to Alzheimer’s, signaling a lack of political will to address this slow-moving pandemic. 

Overall federal funding is down considerably compared to the €1.6 billion commitment of the Sarkozy years. In the Hollande administration, investment fell to €470 million and was spread over multiple diseases.

Restoring funding to previous levels is desperately needed to improve France’s diagnostic infrastructure, which is critical to ensuring early detection of the disease and putting people on the right care pathways before it’s too late. 

France also needs to make sizable investments to boost the country’s supply of trained caregivers. This is essential not simply to create enough supply to meet coming demand, but also to provide relief to family members and loved ones often shoulder this responsibility. As of 2015, these informal caregivers were already providing about €14 billion worth of care – a figure that is surely higher today and completely unsustainable.

According to the Index, France also ranks near the bottom in terms of access to care. This is also because prescriptions for Alzheimer’s therapies have plunged following the health ministry’s 2018 decision to cut all reimbursements.

Reimbursement strategies for Alzheimer’s drugs should also be revisited. This will produce better health outcomes for people who rely on current therapies and boost incentives for investments in new breakthroughs that can slow disease progression. 

President Macron’s new government — and the soon-to-be-elected French parliamentarians — have a unique opportunity to change course, by boosting funding in these key areas. In doing so, they can help France reassume the leadership position it held during the implementation of the 2008-2012 Alzheimer Plan and reduce the long-term economic and social burden of Alzheimer’s. At the same time, they can dramatically improve the lives of millions of its older citizens, their family members and loved ones who will be impacted by this devastating disease. 

Source: Le Monde

Latest Developments

We keep our members and partners in touch with the most recent updates and opinions in the worldwide dialogue on population longevity and related issues.

Brazil Must Fight Antibiotic Resistance

The threat posed by antimicrobial resistance is urgent and spares no country - including Brazil. According to The Lancet, 63 deaths per 100,000 are associated with AMR in Brazil and Paraguay, a rate that exceeds the average for Latin America and the Caribbean. AMR-associated deaths in Brazil are second only to cardiovascular diseases and cancers.

We Missed 100 Million Adult Vaccines – Here’s How We Get Back on Track

Like other pandemics throughout human history, COVID-19 has caused profound changes that are still rippling through our societies, even as people are understandably eager to move on. In fact, these impacts are all the more dangerous when they are largely ignored or effectively invisible. The decline in adult vaccination may be one of the most significant, as a new report finds that ~100 million doses were missed in 2021 and 2022 alone – reversing global progress towards widespread adult immunisation as a new standard of care in a world of more old than young.

New Analysis Shows Lost Ground on Adult Immunisation During the Pandemic with 100 Million Doses Potentially Missed

New data shared today by GSK, in collaboration with the IQVIA Institute for Human Data Science and the Global Coalition on Aging (GCOA), estimate approximately 100 million fewer doses of some adult vaccines (excluding Covid-19 vaccines) were administered in 2021 and 2022 than anticipated, based on the global vaccination adoption trends observed from 2013 to 2020, compounding already low adoption rates pre-pandemic.

Going Beyond Applause: The Potential of Caregiving to Unlock Job Opportunities of the Future

Early in the COVID-19 pandemic, the role of caregivers – staff and family who provide care for older and dependent people to carry out activities such as eating or moving - catapulted to the front of our collective conscience. The daily applause for front-line care workers showed a high level of recognition for their incredible work and provided insight into how our health systems must change as our society ages. We need to continue to recognise caregivers as essential to our ageing society.

High-Level Forum on the Silver Economy 2023

Join us for the High-Level Forum on the Silver Economy 2023. Now in its fourth year, the Silver Economy Forum 2023, December 6 and 7, will explore aging at every stage of life, looking at the growing global Silver Economy through a multigenerational lens. Linking to the goals and aspirations of the UN Decade of Healthy Ageing, SEF 2023 will highlight key themes at the intersection of aging at every age, and the Silver Economy.

Global Coalition on Aging Workshop Calls on G7 Countries to Fund Pull Incentives to Spur Antibiotic Innovation

The Global Coalition on Aging, in partnership with JPMA, today announced the release of its workshop report on the AMR crisis facing G7 countries and the world, “The Value of Pull Incentives in Japan to Encourage Investment in Antibiotic Innovation to Solve the AMR Crisis.” If strong action is not taken to address AMR, we will lose the antibiotics we need to cure infections, which is likely to outpace cancer as a major cause of death, killing an estimated 10 million by 2050.